Table 1 Clinical-pathological characteristics
From: Protective role of intravesical BCG in COVID-19 severity
| Characteristics | Covid-19 patients (n = 43) | All BCG patients (n = 175) |
|---|---|---|
| BCG dosage, mg ± SD | 39.64 ± 22.9 | 44.3 ± 25.5 |
| BCG instillations, n ± SD | 12.20 ± 8.1 | 13.25 ± 7.4 |
| Induction completed, % (n) | 86.0% (37) | 95.4% (167) |
| Maintenance completed, % (n) | 62.8% (27) | 65.1% (114) |
| Maintenance therapy time, years ± SD | 1.48 ± 0.83 | 1.11 ± 0.98 |
| T stage | ||
| Cis, % (n) | 9.3% (4) | 6.3% (11) |
| Ta, % (n) | 55.8% (24) | 48.0% (84) |
| T1, % (n) | 34.9% (15) | 38.9% (68) |
| Previous relapse, % (n) | 55.8% (24) | 42.9% (75) |
| BCG infection (“BCGitis”), % (n) | 25.6% (11) | 18.9% (33) |